Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Wong Mito Lab, |
RCV000503988 | SCV000598428 | likely pathogenic | Mitochondrial DNA depletion syndrome 13 | 2017-08-10 | criteria provided, single submitter | reference population | The NM_012160.4:c.1288C>T (NP_036292.2:p.Arg430Ter) [GRCH38: NC_000006.12:g.98899297G>A] variant in FBXL4 gene is interpretated to be a Likely Pathogenic based on ACMG guidelines (PMID: 25741868). This variant meets one or more of the following evidence codes reported in the ACMG-guideline. PVS1:This variant is a predcted null variant in FBXL4 where loss of function is a known mechanism of disease. PM2:This variant is absent in key population databases. Based on this evidence code ClinGen Pathogenicity Calculator (PMID:28081714) suggested that the variant is Likely Pathogenic. |
Mendelics | RCV000503988 | SCV001137197 | pathogenic | Mitochondrial DNA depletion syndrome 13 | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001857195 | SCV002129352 | pathogenic | not provided | 2023-12-04 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg430*) in the FBXL4 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FBXL4 are known to be pathogenic (PMID: 23993193, 23993194, 25868664). This variant is present in population databases (rs758395213, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with FBXL4-related conditions. ClinVar contains an entry for this variant (Variation ID: 437724). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Gene |
RCV001857195 | SCV002765392 | likely pathogenic | not provided | 2022-06-14 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Has not been previously published as pathogenic or benign to our knowledge |
Fulgent Genetics, |
RCV000503988 | SCV002806094 | likely pathogenic | Mitochondrial DNA depletion syndrome 13 | 2021-10-08 | criteria provided, single submitter | clinical testing | |
Genomics England Pilot Project, |
RCV000503988 | SCV001760192 | likely pathogenic | Mitochondrial DNA depletion syndrome 13 | no assertion criteria provided | clinical testing |